Review
doi: 10.2147/IJGM.S40216.
eCollection 2014.
Management options for the treatment of benign prostatic hyperplasia with or without erectile dysfunction: a focus on tadalafil and patient considerations
Affiliations
- PMID: 24959092
- PMCID: PMC4061160
- DOI: 10.2147/IJGM.S40216
Item in Clipboard
Review
Management options for the treatment of benign prostatic hyperplasia with or without erectile dysfunction: a focus on tadalafil and patient considerations
Int J Gen Med.
.
Abstract
Lower urinary tract symptoms (LUTS) and erectile dysfunction increase with age. Several studies have identified a true association between these two disorders. Basic research studies have shown a significant decrease in the nitric oxide/cyclic guanosine monophosphate pathway with age that leads to decreased relaxation of the bladder wall and prostate and worsening LUTS. In this review article, we will focus on the potential use and clinical significance of phosphodiesterase-5 inhibitors in the treatment of LUTS secondary to benign prostate hyperplasia.
Keywords: lower urinary tract symptoms; phosphodiesterase-5 inhibitors.
Similar articles
-
Update on Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia.Rev Urol. 2012;14(3-4):79-86. Rev Urol. 2012. PMID: 23526698 Free PMC article.
-
Tadalafil for the treatment of benign prostatic hyperplasia.Expert Opin Pharmacother. 2019 Jun;20(8):929-937. doi: 10.1080/14656566.2019.1589452. Epub 2019 Mar 22. Expert Opin Pharmacother. 2019. PMID: 30901259 Review.
-
[Efficiency of phosphodiesterase-5 inhibitors for treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia and concomitant erectile dysfunction].Urologiia. 2019 Sep;(4):130-134. Urologiia. 2019. PMID: 31535819 Russian.
-
Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.Eur Urol. 2016 Jul;70(1):124-133. doi: 10.1016/j.eururo.2015.12.048. Epub 2016 Jan 22. Eur Urol. 2016. PMID: 26806655 Review.
-
Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies.J Urol. 2014 Feb;191(2):405-11. doi: 10.1016/j.juro.2013.09.057. Epub 2013 Oct 1. J Urol. 2014. PMID: 24096120
Cited by
-
Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.Cochrane Database Syst Rev. 2018 Nov 16;11(11):CD010060. doi: 10.1002/14651858.CD010060.pub2. Cochrane Database Syst Rev. 2018. PMID: 30480763 Free PMC article.
-
The role of phosphodiesterase-5 inhibitors in prostatic inflammation: a review.J Inflamm (Lond). 2015 Sep 15;12:54. doi: 10.1186/s12950-015-0099-7. eCollection 2015. J Inflamm (Lond). 2015. PMID: 26379476 Free PMC article. Review.
References
-
- Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132(3):474–479. - PubMed
-
- Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int J Impot Res. 2000;12(6):305–311. - PubMed
-
- Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151(1):54–61. - PubMed
-
- Li MK, Garcia LA, Rosen R. Lower urinary tract symptoms and male sexual dysfunction in Asia: a survey of ageing men from five Asian countries. BJU Int. 2005;96(9):1339–1354. - PubMed
-
- Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7) Eur Urol. 2003;44(6):637–649. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
